* Haemonetics Corp HAE.N HAE is expected to show a rise
in
quarterly revenue when it reports results on February 8.
* The Boston Massachusetts-based company is expected to
report a
11.0% increase in revenue to $266.741 million from $240.37
million a year ago, according to the mean estimate from 5
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Haemonetics Corp is
for
earnings of 73 cents per share. For the same quarter last year,
the company reported earnings of 81 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Haemonetics
Corp
is $70, about 34.2% above its last closing price
of $46.06.
*
This summary was machine generated February 4 at 12:13 GMT. All
figures in US dollars unless otherwise stated